Galectins in Cancer and Translational Medicine: From Bench to Bedside

Bartolazzi, Armando

doi:10.3390/ijms19102934

Cited by 14 publications

(16 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LGALS4 is a protein-coding gene for the protein galectin 4. Galectins are associated with various diseases including cancer and regulate tumor cell adhesion and migration 28 . Moreover, galectin 4 serves as a strong prediction for metastatic potential of adenocarcinomas 29 , a type of carcinoma.…”

Section: Discussionmentioning

confidence: 99%

From multi-omics integration towards novel genomic interaction networks to identify key cancer cell line characteristics

Kuijpers

Kleinjans

Jennen

2021

Sci Rep

View full text Add to dashboard Cite

Cancer is a complex disease where cancer cells express epigenetic and transcriptomic mechanisms to promote tumor initiation, progression, and survival. To extract relevant features from the 2019 Cancer Cell Line Encyclopedia (CCLE), a multi-layer nonnegative matrix factorization approach is used. We used relevant feature genes and DNA promoter regions to construct genomic interaction network to study gene–gene and gene—DNA promoter methylation relationships. Here, we identified a set of gene transcripts and methylated DNA promoter regions for different clusters, including one homogeneous lymphoid neoplasms cluster. In this cluster, we found different methylated transcription factors that affect transcriptional activation of EGFR and downstream interactions. Furthermore, the hippo-signaling pathway might not function properly because of DNA hypermethylation and low gene expression of both LATS2 and YAP1. Finally, we could identify a potential dysregulation of the CD28-CD86-CTLA4 axis. Characterizing the interaction of the epigenome and the transcriptome is vital for our understanding of cancer cell line behavior, not only for deepening insights into cancer-related processes but also for future disease treatment and drug development. Here we have identified potential candidates that characterize cancer cell lines, which give insight into the development and progression of cancers.

show abstract

Section: Discussionmentioning

confidence: 99%

From multi-omics integration towards novel genomic interaction networks to identify key cancer cell line characteristics

Kuijpers

Kleinjans

Jennen

2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Hanahan and Weinberg defined hallmarks of most cancers which describe the biological capabilities essential for carcinogenesis [ 31 ]. There are a number of papers published regarding the subject of cancer (development) and the roles of (targeting) galectins, and even galectin-7 in particular [ 13 , 30 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 ]. Nevertheless, our goal for this section is to provide the reader with a brief overview of the presence and roles of galectin-7 in most cancers/cancer types by covering mostly recent publications.…”

Section: Galectin-7 a Convergence Of Pathology With Physiologymentioning

confidence: 99%

Functions and Inhibition of Galectin-7, an Emerging Target in Cellular Pathophysiology

2021

View full text Add to dashboard Cite

Galectin-7 is a soluble unglycosylated lectin that is able to bind specifically to β-galactosides. It has been described to be involved in apoptosis, proliferation and differentiation, but also in cell adhesion and migration. Several disorders and diseases are discussed by covering the aforementioned biological processes. Structural features of galectin-7 are discussed as well as targeting the protein intracellularly or extracellularly. The exact molecular mechanisms that lie behind many biological processes involving galectin-7 are not known. It is therefore useful to come up with chemical probes or tools in order to obtain knowledge of the physiological processes. The objective of this review is to summarize the roles and functions of galectin-7 in the human body, providing reasons why it is necessary to design inhibitors for galectin-7, to give the reader structural insights and describe its current inhibitors.

show abstract

“…Within several types of tumours, the expression of Gal-1, -3 and -9 has been associated with different clinical phenotypes (Bartolazzi, 2018). Whilst a higher concentration of Gal-1 has been shown to consistently correlate with more aggressive cancer progression, the roles of Gal-3 and Gal-9 appear to be more variable (Camby et al, 2006).…”

Section: Galectins In Systemic Diseasesmentioning

confidence: 99%

“…Clinical applications for galectins are being pursued in areas which are thematically analogous to their functions as outlined in this review. Notably, a recent phase 2 clinical trial has been started for the use of TD139, an inhibitor of Gal-3, in the treatment of idiopathic pulmonary fibrosis (Chan et al, 2018); whilst GR-MD-02, another Gal-3 inhibitor, has been investigated in early clinical trials targeting psoriasis and fibrotic non-alcoholic steatohepatitis (Harrison et al, 2016;Ritchie et al, 2017); other studies in cancer and heart failure are also yielding promising results (Bartolazzi, 2018). Several commercial organisations have been actively pursuing therapeutic applications of galectin inhibitors in various clinical settings over the past few years (Blanchard et al, 2016).…”

Section: Clinical Applications Of Galectins and Future Directionsmentioning

confidence: 99%

Galectins and their involvement in ocular disease and development

Luis

Eastlake

Khaw

et al. 2020

Experimental Eye Research

View full text Add to dashboard Cite

Galectins are carbohydrate binding proteins with high affinity to ß-galactoside containing glycoconjugates. Understanding of the functions of galectins has grown steadily over the past decade, as a result of substantial advancements in the field of glycobiology. Galectins have been shown to be versatile molecules that participate in a range of important biological systems, including inflammation, neovascularisation and fibrosis. These processes are of particular importance in ocular tissues, where a major theme of recent research has been to divert diseases away from pathways which result in loss of function into pathways of repair and regeneration. This review summarises our current understanding of galectins in the context important ocular diseases, followed by an update on current clinical studies and future directions.

show abstract

Galectins in Cancer and Translational Medicine: From Bench to Bedside

Abstract: n/a

Cited by 14 publications

References 32 publications

From multi-omics integration towards novel genomic interaction networks to identify key cancer cell line characteristics

From multi-omics integration towards novel genomic interaction networks to identify key cancer cell line characteristics

Functions and Inhibition of Galectin-7, an Emerging Target in Cellular Pathophysiology

Galectins and their involvement in ocular disease and development

Contact Info

Product

Resources

About